Skip to main content
Toggle Menu of ADA WebSites
ADA Websites
Toggle Search Area
Toggle Menu
e-mail Print Share
Oral Health Topics

Osteoporosis Medications and Medication-Related Osteonecrosis of the Jaw

Key Points

  • Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse effect of bone antiresorptive agents (i.e., bisphosphonates, denosumab) used for osteoporosis.
  • Patients at increased risk of MRONJ include those:
    • receiving the antiresorptive agents at higher dosages and more frequent treatment schedules associated with cancer-related indications, as compared with those for prevention/treatment of osteoporosis;
    • receiving the drugs for more than 2 years;
    • with periodontitis or dentures.
  • Although MRONJ is associated with bone-invasive dental procedures such as tooth extraction, it can also occur without dental intervention.
  • The potential morbidity and mortality associated with osteoporosis-related fracture is considerable and treatment with antiresorptive agents outweighs the low risk of MRONJ in patients with osteoporosis receiving these drugs.
  • A 2011 ADA CSA report developed by an expert panel provides potential treatment management strategies based on expert opinion for patients receiving these drugs for osteoporosis indications and also recommends that “An oral health program consisting of sound hygiene practices and regular dental care may be the optimal approach for lowering [MRONJ] risk” in these patients.
  • Osteoporosis
  • Osteoporosis Medications
  • Medication-Related Osteonecrosis of the Jaw
  • Management of Dental Patients Receiving Antiresorptive Medications for Osteoporosis
  • References
  • ADA Resources
  • Other Resources
  • Appendix
Topic Last Updated: July 28, 2021

Prepared by:

Department of Scientific Information, Evidence Synthesis & Translation Research, ADA Science & Research Institute, LLC.


Content on the Oral Health Topics section of is for informational purposes only.  Content is neither intended to nor does it establish a standard of care or the official policy or position of the ADA; and is not a substitute for professional judgment, advice, diagnosis, or treatment.  ADA is not responsible for information on external websites linked to this website.